Jpmorgan Chase & CO Immunome Inc. Transaction History
Jpmorgan Chase & CO
- $1.14 Trillion
- Q2 2024
A detailed history of Jpmorgan Chase & CO transactions in Immunome Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 23,045 shares of IMNM stock, worth $291,519. This represents 0.0% of its overall portfolio holdings.
Number of Shares
23,045
Previous 728
3065.52%
Holding current value
$291,519
Previous $17,000
1535.29%
% of portfolio
0.0%
Previous 0.0%
Shares
4 transactions
Others Institutions Holding IMNM
# of Institutions
118Shares Held
43.5MCall Options Held
67.2KPut Options Held
65.9K-
Redmile Group, LLC San Francisco, CA4.89MShares$61.9 Million3.86% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA3.88MShares$49.1 Million1.66% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD3.88MShares$49.1 Million0.03% of portfolio
-
Black Rock Inc. New York, NY3.76MShares$47.5 Million0.0% of portfolio
-
Janus Henderson Group PLC London, X03.16MShares$40 Million0.02% of portfolio
About Immunome Inc.
- Ticker IMNM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 12,127,400
- Market Cap $153M
- Description
- Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product ca...